alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 801.57 Discontinuation of legacy FDA identification numbers assigned to devices. ( a ) On the date your device must bear a unique device identifier (UDI) on its label, any National Health-Related Item Code (NHRIC) or National Drug Code (NDC) number assigned to that device is rescinded, and you may no longer provide an NHRIC or NDC number on the label of your device or on any device package.
( b ) If your device is not required to bear a UDI on its label, any NHRIC or NDC number assigned to that device is rescinded as of September 24, 2018, and beginning on that date, you may no longer provide an NHRIC or NDC number of the label of your device or on any device package.
( c ) A labeler who has been assigned an FDA labeler code to facilitate use of NHRIC or NDC numbers may continue to use that labeler code under a system for the issuance of UDIs, *provided that*— ( 1 ) Such use is consistent with the framework of the issuing agency that operates that system; and
( 2 ) No later than September 24, 2014, the labeler submits, and obtains FDA approval of, a request for continued use of the assigned labeler code. A request for continued use of an assigned labeler code must be submitted by email to: *GUDIDSupport@fda.hhs.gov ,* or by correspondence to: UDI Regulatory Policy Support, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3293, Silver Spring, MD 20993-0002.
( d ) Each request for continued use of an assigned labeler code must provide— ( 1 ) The name, mailing address, email address, and phone number of the labeler who is currently using the labeler code;
( 2 ) The owner/operator account identification used by the labeler to submit registration and listing information using FDA's Unified Registration and Listing System (FURLS).
( 3 ) The FDA labeler code that the labeler wants to continue using.
[78 FR 58820, Sept. 24, 2013, as amended at 81 FR 11428, Mar. 4, 2016; 85 FR 18441, Apr. 2, 2020]
[Federal Register Volume 75, Number 44 (Monday, March 8, 2010)]
[Notices]
[Page 10489]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4584]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Eye Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Eye Institute Special Emphasis 
Panel; NEI Clinical Grant Applications and Cooperative Agreements.
    Date: April 12, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military 
Road, NW., Washington, DC 20015.
    Contact Person: Anne E Schaffner, PhD, Scientific Review 
Officer, Division of Extramural Research, National Eye Institute, 
5635 Fishers Lane, Suite 1300, Msc 9300, Bethesda, MD 20892-9300, 
(301) 451-2020, <a href="/cdn-cgi/l/email-protection#12737761527c777b3c7c7b7a3c757d64"><span class="__cf_email__" data-cfemail="62030711220c070b4c0c0b0a4c050d14">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, 
Vision Research, National Institutes of Health, HHS)

    Dated: February 25, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-4584 Filed 3-5-10; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
§ 680.3 Tests. ( a ) *Identity.* When a specific identity test meeting the provisions of § 610.14 of this chapter cannot be performed, the manufacture of each lot shall be separated from the manufacture of other products in a manner that will preclude adulteration, and records made in the course of manufacture shall be in sufficient detail to verify the identity of the product.
( b ) [Reserved]
( c ) *Sterility.* A sterility test shall be performed on each lot of each Allergenic Product as required by § 610.12 of this chapter.
( d ) [Reserved]
( e ) *Potency.* The potency of each lot of each Allergenic Product shall be determined as prescribed in § 610.10 of this chapter. Except as provided in this section, the potency test methods shall measure the allergenic activity of the product. Until manufacturers are notified by the Director, Center for Biologics Evaluation and Research, of the existence of a potency test that measures the allergenic activity of an allergenic product, manufacturers may continue to use unstandardized potency designations.
( f ) *Records.* The records related to the testing requirements of this section shall be prepared and maintained as required by §§ 211.165, 211.167, 211.188, and 211.194 of this chapter.
[38 FR 32100, Nov. 20, 1973, as amended at 39 FR 19777, June 6, 1974; 41 FR 4015, Jan. 28, 1976; 52 FR 37607, Oct. 8, 1987; 55 FR 11013, Mar. 26, 1990; 67 FR 9587, Mar. 4, 2002; 77 FR 26175, May 3, 2012; 77 FR 30884, May 24, 2012; 80 FR 37974, July 2, 2015]
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL   INFORMATION  EXTRACTED  FROM  THE
CONSOLIDATED  BALANCE  SHEETS  (UNAUDITED)  AS OF AUGUST 2, 1998 AND NOVEMBER 2,
1997 AND THE CONSOLIDATED  STATEMENTS OF OPERATIONS (UNAUDITED) FOR THE QUARTERS
ENDED AUGUST 2, 1998 AND AUGUST 3, 1997
</LEGEND>
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          NOV-01-1998
<PERIOD-START>                             NOV-03-1997
<PERIOD-END>                               AUG-02-1998
<EXCHANGE-RATE>                                      1
<CASH>                                          41,950
<SECURITIES>                                         0
<RECEIVABLES>                                  417,731
<ALLOWANCES>                                    17,688
<INVENTORY>                                    432,855
<CURRENT-ASSETS>                               887,163
<PP&E>                                         193,760
<DEPRECIATION>                                 100,036
<TOTAL-ASSETS>                               1,118,873
<CURRENT-LIABILITIES>                          820,467
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           200
<OTHER-SE>                                     283,357
<TOTAL-LIABILITY-AND-EQUITY>                 1,118,873
<SALES>                                      3,947,207
<TOTAL-REVENUES>                             3,947,207
<CGS>                                        3,702,130
<TOTAL-COSTS>                                3,720,130
<OTHER-EXPENSES>                                 5,600
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               3,791
<INCOME-PRETAX>                               (18,520)
<INCOME-TAX>                                   (6,473)
<INCOME-CONTINUING>                           (12,047)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (12,047)
<EPS-PRIMARY>                                   (0.61)
<EPS-DILUTED>                                   (0.61)
        

</TABLE>
<PAGE>
                                                                    Exhibit 23.2

            CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8 (File Nos. 333-53374, 333-105963 and 333-127025) and
Form S-3 (File Nos. 333-106126, 333-117264, 333-119864, 333-128074, and
333-138748) of Evergreen Solar, Inc. of our report dated February 27, 2007
relating to the financial statements of EverQ GmbH, which appears in this
Annual Report on Form 10-K/A for the year ended December 31, 2006.

/s/ PricewaterhouseCoopers AG

Leipzig, Germany
April 27, 2007
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          SEP-30-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               MAR-31-1999
<CASH>                                           2,271
<SECURITIES>                                         0
<RECEIVABLES>                                   90,405
<ALLOWANCES>                                         0
<INVENTORY>                                     53,004
<CURRENT-ASSETS>                               151,314
<PP&E>                                         140,681
<DEPRECIATION>                                (63,350)
<TOTAL-ASSETS>                                 313,994
<CURRENT-LIABILITIES>                           72,352
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        42,294
<OTHER-SE>                                      41,438
<TOTAL-LIABILITY-AND-EQUITY>                   313,994
<SALES>                                        115,202
<TOTAL-REVENUES>                               115,202
<CGS>                                           84,692
<TOTAL-COSTS>                                  109,075
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               2,499
<INCOME-PRETAX>                                  3,628
<INCOME-TAX>                                     1,270
<INCOME-CONTINUING>                              2,358
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     2,358
<EPS-PRIMARY>                                      .18
<EPS-DILUTED>                                      .16
        

</TABLE>
FIRST DISTRICT COURT OF APPEAL

STATE OF FLORIDA

_____________________________

No. 1D18-545

_____________________________

FLORIDA INVESTORS CAPITAL,

LLC,

Appellant,

v.

UNITED SECURITY FINANCIAL 

CORP.,

Appellee.

_____________________________

On appeal from the Circuit Court for Okaloosa County.

Terrance R. Ketchel, Judge.

November 28, 2018

PER CURIAM.

AFFIRMED.

RAY, KELSEY, and JAY, JJ., concur.

_____________________________

Not final until disposition of any timely and 

authorized motion under Fla. R. App. P. 9.330 or 

9.331.

_____________________________
2

Ivan D. Ivanov of The Ivanov Law Firm, P.A., Tampa, for 

Appellant.

Anthony R. Smith and Matthew R. Feluren of Sirote & Permutt, 

P.C., Fort Lauderdale, for Appellee United Security Financial 

Corp.
EXHIBIT 31.1





CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)



I, David F. Levy, certify that:



1. I have reviewed this quarterly report of InZon Corporation;



2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;



3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;



4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and have:



(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;



(b) Evaluated the effectiveness of the small business issuers disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and



(c) Disclosed in this report any change in the small business issuers internal control over financial reporting that occurred during the small business issuers most recent fiscal quarter (the small business issuers fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuers internal control over financial reporting; and



5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the small business issuers auditors and the audit committee of the small business issuers board of directors (or persons performing the equivalent functions):



(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuers ability to record, process, summarize and report financial information; and



(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuers internal control over financial reporting.





|                      |     |                        
|--------------------- | --- | -----------------------
|Date: August 14, 2007 | By: | /s/ David F. Levy      
|                      |     | David F. Levy          
|                      |     | Chief Executive Officer
NO. 12-10-00016-CR

IN THE COURT OF APPEALS

TWELFTH COURT OF APPEALS DISTRICT

TYLER, TEXAS

QUILLON AKMON BROWN, § APPEAL FROM THE 7TH

APPELLANT

V. § JUDICIAL DISTRICT COURT 

THE STATE OF TEXAS,

APPELLEE § SMITH COUNTY, TEXAS

MEMORANDUM OPINION

PER CURIAM

Appellant has filed a motion to dismiss this appeal. The motion is signed by Appellant and 

by his counsel. No decision having been delivered by this court, the motion is granted, and the 

appeal is dismissed in accordance with Texas Rule of Appellate Procedure 42.2.

Opinion delivered May 19, 2010.

Panel consisted of Worthen, C.J., Griffith, J., and Hoyle, J.

(DO NOT PUBLISH)
Exhibit 21

                      SUBSIDIARY AND PRINCIPAL INVESTMENTS

Subsidiaries*

Zarlink Semiconductor (U.S.) Inc.
U.S.A.

Zarlink Semiconductor V.N. Inc.
U.S.A.

Zarlink Semiconductor Limited
Great Britain

Zarlink Semiconductor AB
Sweden

Zarlink Semiconductor SA
(France)

Zarlink Semiconductor (Asia) Pte. Ltd.
(Singapore)

Zarlink Semiconductor Japan KK
(Japan)

Zarlink Semiconductor (Barbados) Ltd.
Barbados

Principal Investments

Optenia, Inc.
(Canada)

Mitel Networks Corporation
(Canada)

Silicon Bridge, Inc.
(U.S.A.)

X Integrated Circuits B.V.
(Netherlands)

*     All  subsidiaries  are  100%  owned,  directly  or  indirectly,  by  Mitel
      Corporation.
CONSENTOF INDEPENDENT ACCOUNTANTS

We hereby consent to theincorporation by reference in the Registration Statements (Forms F-3No. 333-12096, No. 333-13550 and No. 333-84510 and Form S-8 No.333-106591) of Deutsche Telekom AG and in the related Prospectuses ofour report dated March 11, 2004, with respect to the consolidatedfinancial statements of Deutsche Telekom AG included in this AnnualReport on Form 20F for the year ended December 31, 2003.

March 29, 2004

Ernst& YoungDeutsche Allgemeine TreuhandAGWirtschaftspruefungsgesellschaft Stuttgart

|                                                                                           |  |                    |  |  |  |  |
|-------------------------------------------------------------------------------------------|--|--------------------|--|--|--|--|
| (Prof. Dr.Pfitzer)                                                                        |  | (Hollweg)          |
| Wirtschaftspruefer                                                                        |  | Wirtschaftspruefer |
| PwC Deutsche RevisionAktiengesellschaft Wirtschaftspruefungsgesellschaft Frankfurtam Main |  |
| (Frings)                                                                                  |  | (Laue)             |
| Wirtschaftspruefer                                                                        |  | Wirtschaftspruefer |
|                                                                                           |

----
Editorial Note on Part 102
Editorial Note: Nomenclature changes to part 102 appear at 81 FR 49895, July 29, 2016.

§ 102.54 Seafood cocktails. The common or usual name of a seafood cocktail in package form fabricated with one or more seafood ingredients shall be: ( a ) When the cocktail contains only one seafood ingredient, the name of the seafood ingredient followed by the word “cocktail” (e.g., shrimp cocktail, crabmeat cocktail) and a statement of the percentage by weight of that seafood ingredient in the product in the manner set forth in § 102.5(b).
( b ) When the cocktail contains more than one seafood ingredient, the term “seafood cocktail” and a statement of the percentage by weight of each seafood ingredient in the product in the manner set forth in § 102.5(b).
# C_2016156EN.01004301.xml

| 2.5.2016 | EN | Official Journal of the European Union | C 156/43 |
| --- | --- | --- | --- |

2.5.2016

EN

Official Journal of the European Union

C 156/43

---

Order of the General Court of 15 March 2016 — Larymnis Larko v Commission

(Case T-576/14) (1)

1

((Action for annulment - State aid - Privatisation - Support measures for a debtor of the applicant - Decision declaring the aid to be incompatible with the internal market - No interest in bringing proceedings - Inadmissibility))

(2016/C 156/57)

Language of the case: Greek

Parties

Parties

Applicant: Elliniki Metalleftiki kai Metallourgiki Larymnis Larko AE (Kallithea, Greece) (represented by: V. Koulouris, lawyer)

Applicant:

Defendant: European Commission (represented by: A. Bouchagiar, acting as Agent, and by V. Chatzopoulos, lawyer)

Defendant:

Re:

Re:

Application for annulment of Commission Decision C (2014) 1805 of 27 March 2014 declaring that the sale of some of the assets exploited by Larko General Mining & Metallurgical Company SA did not constitute State aid [SA. 37954 (2013/N)].

Operative part of the order

Operative part of the order

| 1. | The action is dismissed as inadmissible. |
| --- | --- |

1.

The action is dismissed as inadmissible.

| 2. | Elliniki Metalleftiki kai Metallourgiki Larymnis Larko AE shall bear its own costs and pay those incurred by the European Commission. |
| --- | --- |

2.

Elliniki Metalleftiki kai Metallourgiki Larymnis Larko AE shall bear its own costs and pay those incurred by the European Commission.

---

(1)  OJ C 395, 10.11.2014.

1

---
#### § 520.1872 Praziquantel, pyrantel pamoate, and febantel tablets.

(a) *Specifications.* Each tablet or chewable tablet contains either:

(1) Tablet No. 1: 22.7 milligrams praziquantel, 22.7 milligrams pyrantel base, and 113.4 milligrams febantel; or

(2) Tablet No. 2: 68 milligrams praziquantel, 68 milligrams pyrantel base, and 340.2 milligrams febantel.

(3) Tablet No. 3: 136 milligrams (mg) praziquantel, 136 mg pyrantel base, and 680.4 mg febantel.

(b) *Sponsor.* See No. 058198 in [§ 510.600(c) of this chapter](/on/2024-09-17/title-21/section-510.600#p-510.600(c)).

(c) *Conditions of use* —

(1) *Dogs* —

(i) *Amount.* Administer as a single dose directly by mouth or in a small amount of food as follows:

| Weight of animal | | Number of tablets per dose | | |
| --- | --- | --- | --- | --- |
| Kilograms | Pounds | Tablet no. 1 | Tablet no. 2 | Tablet no. 3 |
| 0.9 to 1.8 | 2 to 4 | 1/2 | | |
| 2.3 to 3.2 | 5 to 7 | 1 | | |
| 3.6 to 5.4 | 8 to 12 | 1 1/2 | | |
| 5.9 to 8.2 | 13 to 18 | 2 | | |
| 8.6 to 11.4 | 19 to 25 | 2 1/2 | | |
| 11.8 to 13.6 | 26 to 30 | | 1 | |
| 14.1 to 20.0 | 31 to 44 | | 1 1/2 | |
| 20.4 to 27.2 | 45 to 60 | | 2 | 1 |
| 27.7 to 40.9 | 61 to 90 | | | 1 1/2 |
| 41.3 to 54.5 | 91 to 120 | | | 2 |

(ii) *Indications for use.* For the removal of tapeworms (*Dipylidium caninum, Taenia pisiformis, Echinococcus granulosus*); hookworms (*Ancylostoma caninum, Uncinaria stenocephala*); ascarids (*Toxocara canis, Toxascaris leonina*); and whipworms (*Trichuris vulpis*) and for the removal and control of tapeworm *Echinococcus multilocularis* in dogs.

(iii) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]

[[59 FR 33908](https://www.federalregister.gov/citation/59-FR-33908), July 1, 1994, as amended at [61 FR 29651](https://www.federalregister.gov/citation/61-FR-29651), June 12, 1996; [68 FR 22293](https://www.federalregister.gov/citation/68-FR-22293), Apr. 28, 2003; [71 FR 6677](https://www.federalregister.gov/citation/71-FR-6677), Feb. 9, 2006; [86 FR 14819](https://www.federalregister.gov/citation/86-FR-14819), Mar. 19, 2021; [87 FR 58961](https://www.federalregister.gov/citation/87-FR-58961), Sept. 29, 2022]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3820 *Treponema pallidum* nontreponemal test reagents. ( a ) *Identification. Treponema pallidum* nontreponemal test reagents are devices that consist of antigens derived from nontreponemal sources (sources not directly associated with treponemal organisms) and control sera (standardized sera with which test results are compared) used in serological tests to identify reagin, an antibody-like agent, which is produced from the reaction of treponema microorganisms with body tissues. The identification aids in the diagnosis of syphilis caused by microorganisms belonging to the genus *Treponema* and provides epidemiological information on syphilis.
( b ) *Classification.* Class II (performance standards).